Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-FDCK or Codeine or Semaglutide

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (2) · (multiple, generic dominant) (1) · Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM) (1)
classes:
Analgesic (2) · Dissociative (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · [[Cardiovascular risk reduction]] agent (1)
mechanism:
Long-acting agonist of the [[GLP-1 receptor]]. (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · NMDA antagonist; fluorinated ketamine analogue (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)
uses:
None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · [[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM (1)
starting dose:
None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Ozempic: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000245-QINU`"' · Wegovy: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000246-QINU`"' · Rybelsus: 3 mg PO daily × 30 d'"`UNIQ--ref-00000247-QINU`"' (1)
preparations:
None (2) · Pre-filled multi-dose pen (0.25 / 0.5 / 1 / 2 mg, Ozempic;'"`UNIQ--ref-00000248-QINU`"' 0.25 / 0.5 / 1 / 1.7 / 2.4 mg, Wegovy'"`UNIQ--ref-00000249-QINU`"') · Oral tablet 3 / 7 / 14 mg co-formulated with SNAC absorption enhancer (Rybelsus)'"`UNIQ--ref-0000024A-QINU`"' (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (2) · 2 mg/wk SC (Ozempic)'"`UNIQ--ref-0000024B-QINU`"' · 2.4 mg/wk SC (Wegovy)'"`UNIQ--ref-0000024C-QINU`"' · 14 mg PO daily (Rybelsus)'"`UNIQ--ref-0000024D-QINU`"' (1) · 360 mg/day (1)
routes:
None (2) · on empty stomach with ≤120 mL water (1) · PO (only formulation marketed in the US). (1) · Subcutaneous (abdomen (1) · thigh (1) · upper arm)'"`UNIQ--ref-0000024E-QINU`"' · Oral (Rybelsus only (1) · ≥30 min before any food/drink/other oral medicine)'"`UNIQ--ref-0000024F-QINU`"' (1)
onset:
None (2) · 30–60 min (PO) (1) · Glycemic effect within days;<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> full weight effect over months'"`UNIQ--ref-00000250-QINU`"' (1)
duration:
None (2) · 4–6 hours (1) · ~7 days (weekly SC dosing)'"`UNIQ--ref-00000251-QINU`"' · ~24 h (oral)'"`UNIQ--ref-00000252-QINU`"' (1)
halflife:
None (2) · 2.5–3 hours (1) · ~165 hours (~1 week), among the longest of any GLP-1 RA'"`UNIQ--ref-00000253-QINU`"' (1)
bioavailability:
None (2) · SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (3) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)
legal:
None (2) · Rx-only;'"`UNIQ--ref-00000256-QINU`"' not a controlled substance (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 4 results in range #1 to #4.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"